Evidence map›Paper›PMID 39794701›Full record

ArticleCellular & molecular biology letters2025

Effect of SNORD113-3/ADAR2 on glycolipid metabolism in glioblastoma via A-to-I editing of PHKA2.

Zheng Cui, Xiaobai Liu, Tiange E, Hongda Lin, Di Wang, Yunhui Liu, Xuelei Ruan, Ping Wang, Libo Liu, Yixue Xue

Abstract read
In one paragraph

Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Selective remodeling of snoRNA and sdRNA biology in glioblastoma.Frontiers in cell and developmental biology · 2026
    Review
  7. Review
  8. Targeting RNA adenosine editing and modification enzymes for RNA therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zheng CuiDepartment of Neurology, The First Affiliated Hospital, China Medical University, Shenyang, 110001, Liaoning, China.
Xiaobai LiuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Tiange EDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Hongda LinDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Di WangDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Yunhui LiuDepartment of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Xuelei RuanKey Laboratory of Neuro-Oncology in Liaoning Province, Shenyang, 110004, China.
Ping WangKey Laboratory of Neuro-Oncology in Liaoning Province, Shenyang, 110004, China.
Libo LiuKey Laboratory of Neuro-Oncology in Liaoning Province, Shenyang, 110004, China.
Yixue XueKey Laboratory of Neuro-Oncology in Liaoning Province, Shenyang, 110004, China. 15804086963@163.com.

Funding

National Natural Science Foundation of China 82173071National Natural Science Foundation of China 82272846
6 · The paper itself

Abstract

backgroundGlioblastoma multiforme (GBM) is a highly aggressive brain tumor, characterized by its poor prognosis. Glycolipid metabolism is strongly associated with GBM development and malignant behavior. However, the precise functions of snoRNAs and ADARs in glycolipid metabolism within GBM cells remain elusive. The objective of the present study is to delve into the underlying mechanisms through which snoRNAs and ADARs exert regulatory effects on glycolipid metabolism in GBM cells.

methodsRNA immunoprecipitation and RNA pull-down experiments were conducted to verify the homodimerization of ADAR2 by SNORD113-3, and Sanger sequencing and Western blot experiments were used to detect the A-to-I RNA editing of PHKA2 mRNA by ADAR2. Furthermore, the phosphorylation of EBF1 was measured by in vitro kinase assay. Finally, in vivo studies using nude mice confirmed that SNORD113-3 and ADAR2 overexpression, along with PHKA2 knockdown, could suppress the formation of subcutaneous xenograft tumors and improve the outcome of tumor-bearing nude mice.

resultsWe found that PHKA2 in GBM significantly promoted glycolipid metabolism, while SNORD113-3, ADAR2, and EBF1 significantly inhibited glycolipid metabolism. SNORD113-3 promotes ADAR2 protein expression by promoting ADAR2 homodimer formation. ADAR2 mediates the A-to-I RNA editing of PHKA2 mRNA. Mass spectrometry analysis and in vitro kinase testing revealed that PHKA2 phosphorylates EBF1 on Y256, reducing the stability and expression of EBF1. Furthermore, direct binding of EBF1 to PKM2 and ACLY promoters was observed, suggesting the inhibition of their expression by EBF1. These findings suggest the existence of a SNORD113-3/ADAR2/PHKA2/EBF1 pathway that collectively regulates the metabolism of glycolipid and the growth of GBM cells. Finally, in vivo studies using nude mice confirmed that knockdown of PHKA2, along with overexpression of SNORD113-3 and ADAR2, could obviously suppress GBM subcutaneous xenograft tumor formation and improve the outcome of those tumor-bearing nude mice.

conclusionsHerein, we clarified the underlying mechanism involving the SNORD113-3/ADAR2/PHKA2/EBF1 pathway in the regulation of GBM cell growth and glycolipid metabolism. Our results provide a framework for the development of innovative therapeutic interventions to improve the prognosis of patients with GBM.

Indexed as

Adenosine DeaminaseBrain NeoplasmsGlioblastomaGlycolipidsRNA-Binding ProteinsRNA EditingAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceMice, NudeTrans-ActivatorsAdenosine DeaminaseGlycolipidsRNA-Binding ProteinsTrans-ActivatorsADAR2A-to-I RNA editingGliomaGlycolipid metabolismPhosphorylation

Identifiers

PMID39794701
PMCPMC11724473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.